SPF 45+ Dry Shampoo Aims to Shield Scalp from UV Damage and Skin Cancer

For healthcare professionals tracking the convergence of dermatology and consumer health, Solésence's latest launch marks a notable development. By embedding a high SPF into a dry shampoo, the company addresses an overlooked skin cancer risk: UV exposure on the scalp. Clinical evidence backing the formulation could set a new standard for ancillary sun protection products.

Solésence, Inc. (Nasdaq: SLSN) has announced the launch of two new scalp care products—Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen—marking a deliberate expansion into the hair and scalp segment. The announcement, made via press release on July 13, 2026, positions these offerings as market-ready solutions available globally to brand partners. This move is the second pillar of the company's ongoing Transform and Transcend initiative, which leverages its proprietary WHSPR™ and Kleair™ technology suites to embed skin health claims into high-growth beauty categories.

“

The Revitalizing Scalp Serum incorporates the patented WHSPR™ technology alongside 5% niacinamide, with the company asserting clinically proven improvements in barrier recovery, erythema reduction, scalp moisturization, and sebum control.

The scalp care market has emerged as a compelling white space within the broader beauty and personal care industry. Consumers increasingly view scalp health as integral to hair vitality—a trend that has fueled demand for products addressing irritation, dryness, UV damage, and even skin cancer risk on the scalp. Solésence claims its new products directly target these concerns. The Revitalizing Scalp Serum incorporates the patented WHSPR™ technology alongside 5% niacinamide, with the company asserting clinically proven improvements in barrier recovery, erythema reduction, scalp moisturization, and sebum control. The Scalp Screen Dry Shampoo SPF 45+ Sunscreen, meanwhile, combines oil-absorbing dry shampoo functionality with high-level sun protection—an unusual combination that could capture the attention of dermatologists and sun-conscious consumers.

For Solésence, a firm that operates at the intersection of beauty and life sciences, this launch is a strategic extension of its business model. Rather than marketing directly to consumers, the company develops scientifically backed, patent-protected formulations and then licenses or sells them to established beauty brands. This B2B approach allows Solésence to scale innovation quickly while brand partners benefit from ready-to-market, differentiated products. The inclusion of WHSPR™ and Kleair™ technologies—both globally patented—erects a competitive moat, presumably enabling pricing power and exclusivity agreements.

From a clinical perspective, the products' ability to deliver on their promises will determine long-term credibility. The press release cites “clinically validated performance” but does not detail study designs, sample sizes, or quantitative endpoints beyond mentions of barrier recovery and erythema mitigation. Healthcare professionals and regulatory bodies will likely demand more granular data before endorsing these benefits as medical-grade. However, the SPF 45+ claim is straightforward: it implies adequate protection against UVB rays, though the water resistance and UVA protection (PA rating) are not disclosed. For a dry shampoo—typically an aesthetic product—incorporating sunscreen at this level is innovative, but real-world efficacy depends on even application and reapplication compliance, aspects that remain unaddressed.